Formiminoglutamic aciduria is a rare genetic condition that affects how the body breaks down the amino acid histidine. People with Formiminoglutamic aciduria may have feeding issues, developmental delays, or learning differences, and some have seizures. Signs often start in infancy or early childhood and can be lifelong, but not everyone will have the same experience. Treatment focuses on folinic acid (a form of folate), nutrition support, and therapy services, and early symptoms of Formiminoglutamic aciduria may improve with care. The outlook varies, but many people with Formiminoglutamic aciduria can do well with early diagnosis and ongoing follow-up.
Overview
Formiminoglutamic aciduriaSymptoms
Formiminoglutamic aciduria may cause no noticeable problems. When features occur, they can include developmental and speech delay, learning difficulties, low muscle tone, poor weight gain, and a type of anemia causing tiredness and pale skin. Some infants have feeding issues.
Outlook and prognosis
Most people with formiminoglutamic aciduria lead active lives, especially when folate and vitamin B12 needs are met and infections or fasting are avoided. Early symptoms of formiminoglutamic aciduria often ease with tailored nutrition and prompt care. Regular follow‑up helps protect growth, learning, and energy.
Causes and risk factors
Formiminoglutamic aciduria most often results from autosomal recessive FTCD gene variants. Risk rises when both parents are carriers or are closely related; new mutations are possible. Low folate intake, folate‑depleting medicines, or infections or illnesses can worsen or reveal formiminoglutamic aciduria.
Genetic influences
Genetics is central in formiminoglutamic aciduria, usually caused by inherited changes in the FTCD gene. These variants disrupt folate‑related processing of the amino acid histidine, leading to excessive formiminoglutamate. Most cases are autosomal recessive; carrier testing and family counseling can help.
Diagnosis
Diagnosis relies on clinical features with biochemical testing showing excess FIGLU in urine or blood, sometimes after a histidine challenge. Genetic tests confirming FTCD variants establish the genetic diagnosis of Formiminoglutamic aciduria. Doctors also check folate levels to exclude mimics.
Treatment and drugs
Treatment for formiminoglutamic aciduria focuses on addressing folate-related pathways and supporting growth and development. Care may include folinic acid (leucovorin), vitamin B12 when indicated, and a protein-managed diet tailored by a metabolic team. Regular monitoring helps adjust therapy and track learning, behavior, and nutrition.
Symptoms
Day to day, many people with formiminoglutamic aciduria feel well and have no obvious issues. When signs do appear, early features of formiminoglutamic aciduria may involve slow speech development, low muscle tone, or poor weight gain in infancy. Some develop a type of anemia that can cause tiredness and pale skin. Features vary from person to person and can change over time.
Many people feel well and have no clear day-to-day problems. It’s sometimes found on a routine newborn screen or urine test rather than from symptoms.
Motor or social milestones can take longer than expected. Early intervention services can support skills at each stage.
Words may come later, and understanding directions can take extra effort. In daily routines, this might show up as small but noticeable changes.
Muscles can feel floppy, and holding up the head or sitting may be delayed. Physical and occupational therapy often help build strength and coordination.
How people usually first notice Formiminoglutamic aciduria?
Many families first notice something is off in infancy or early childhood, often when a baby has trouble gaining weight, seems unusually tired or irritable, or misses early milestones like sitting or babbling on time; some have frequent infections or feeding difficulties. Doctors may pick up the first signs of formiminoglutamic aciduria during routine check-ups or after blood and urine tests show unusually high levels of a substance called FIGLU, especially if there’s concern about folate or vitamin B12 pathways. In some places it’s found through follow-up metabolic testing after an abnormal newborn screen or when a child with developmental delays is evaluated for a metabolic cause.
Types of Formiminoglutamic aciduria
Formiminoglutamic aciduria is a genetic condition with a few recognized clinical variants. These variants are defined by changes in the FTCD gene that affect the same enzyme in different ways, which can shift how noticeable symptoms are and when they appear. Not everyone will experience every type. Clinicians often describe them in these categories:
Typical FTCD deficiency
This classic variant involves low activity of the FTCD enzyme, leading to high formiminoglutamate (FIGLU) levels in urine and sometimes mild anemia. Many children have normal growth and development, while a subset may show speech or learning delays.
Newborn-screening variant
Detected through elevated markers on newborn screening, this type often has FIGLU in urine but few or no day-to-day symptoms. For many, certain types stand out more than others.
Severe early-onset
Rare, more pronounced deficiency may present in infancy with feeding difficulties, poor weight gain, and more noticeable developmental delays. Doctors may also see stronger lab abnormalities like significant FIGLU elevation and megaloblastic anemia.
What genetics can tell you about symptoms
Some people with FTCD gene changes develop anemia, slow growth, or developmental delays because their bodies struggle to process folate-linked steps in breaking down histidine. Variants that strongly reduce FTCD enzyme activity tend to cause earlier, more noticeable symptoms in infancy or childhood.
Causes and risk factors
The main causes of Formiminoglutamic aciduria are an inherited enzyme problem or low folate in the body. Inherited cases happen when both FTCD gene copies change and the enzyme that handles histidine is low. Low folate risk rises with limited diets, heavy alcohol use, and higher needs during pregnancy or growth. Gut conditions that hinder absorption and some cancer, seizure, or antibiotic medicines can raise risk by lowering folate. Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Understanding what raises the chance of formiminoglutamic aciduria can help families plan care around pregnancy and the newborn period. Doctors often group risks into internal (biological) and external (environmental). Here, we focus on body-based factors and exposures—not genetics or lifestyle habits—that can make this condition more likely. This also helps explain why early symptoms of formiminoglutamic aciduria can look different from one baby to another.
During pregnancy, low folate in the mother can limit the baby’s folate stores. This can raise the chance of formiminoglutamic aciduria at birth.
Low B12 can block how folate works in the body. This functional block can lead to the same buildup seen in formiminoglutamic aciduria.
Some cancer drugs, certain seizure medicines, and a few antibiotics interfere with folate pathways. Exposure during pregnancy can increase the likelihood of this condition in a newborn.
Gut conditions or prior stomach or intestinal surgery can reduce folate and B12 uptake. Reduced absorption during pregnancy can raise risk for formiminoglutamic aciduria in the baby.
Genetic risk factors
Formiminoglutamic aciduria (also called FTCD deficiency) results from changes in the FTCD gene that reduce the activity of a two-part enzyme involved in histidine breakdown. In simple terms, the genetic causes of Formiminoglutamic aciduria are inherited changes passed down in an autosomal recessive pattern: a child is affected only when they receive two nonworking copies, one from each parent. Carriers usually feel well and are identified through family or newborn testing. Carrying a genetic change doesn’t guarantee the condition will appear.
FTCD gene variants: Changes in the FTCD gene reduce the activity of a two-part enzyme needed to process histidine. Low activity causes formiminoglutamate to build up, which is what testing detects. Different variants can lead to different levels of enzyme function.
Autosomal recessive: Two altered copies are required for Formiminoglutamic aciduria to appear—one inherited from each parent. If both parents are carriers, each pregnancy has a 25% (1 in 4) chance of an affected child. Siblings can have different outcomes by chance.
Carrier parents: People who carry a single FTCD change typically have no symptoms. They can pass the change to children even if they feel well. Genetic counseling can explain personal and family risks.
Domain-specific effects: FTCD has two working parts, and some variants mainly affect one part more than the other. This can lead to partial enzyme activity and milder lab findings in some people. Clinical features may vary even within the same family.
Family history: Having a sibling with Formiminoglutamic aciduria increases the chance that future children will also be affected. Other relatives may be healthy carriers without knowing it. Testing at-risk family members can clarify who carries the variant.
Parental relatedness: Parents who are blood relatives have a higher chance of carrying the same FTCD variant. This raises the likelihood that a child inherits two altered copies. The overall risk still depends on the specific variants in the family.
Lifestyle risk factors
This is a genetic, congenital condition; lifestyle habits do not cause it, but they can influence symptom control and day-to-day stability. Understanding how lifestyle affects Formiminoglutamic aciduria can help reduce metabolite buildup, anemia, and fatigue. Below are practical lifestyle risk factors for Formiminoglutamic aciduria to consider in daily routines.
Large amounts of histidine-rich foods can increase FIGLU production and urinary losses. Choosing lower-histidine protein options and avoiding big single servings may reduce metabolite buildup.
Inadequate folate intake can worsen impaired one-carbon transfer and raise FIGLU or anemia risk. Regular folate-rich foods or prescribed folate/folinic acid can support metabolic balance.
Prolonged fasting increases protein breakdown, raising histidine flux and FIGLU. Regular meals and snacks, especially during busy days, can blunt catabolism.
Illness can trigger catabolic stress and higher FIGLU. Early hydration and adequate carbohydrates during illness can help stabilize metabolism.
Risk prevention
Formiminoglutamic aciduria is a genetic condition, so you can’t prevent it from existing, but you can lower the chance of complications and support long‑term health. Prevention isn’t about perfection, it’s about small steps that add up. The main goals are to keep folate and vitamin B12 status healthy, watch for anemia or growth concerns early, and plan ahead for times of stress like illness or pregnancy. Partnering with your care team helps tailor steps to your needs over time.
Eating folate-rich foods (leafy greens, beans, fortified grains) supports the pathway affected in Formiminoglutamic aciduria. A folic acid supplement may be recommended; ask your clinician about dose.
Low B12 can worsen tiredness and anemia. Periodic B12 testing and supplementation if needed help red blood cells form properly.
Some medicines reduce folate action and may aggravate anemia in Formiminoglutamic aciduria. Share all prescriptions and supplements so your team can adjust doses or add folate support if needed.
Periodic visits can catch anemia, growth changes, or learning needs early. Simple tests like a complete blood count and folate/B12 levels guide care. Screenings and check-ups are part of prevention too.
Transmission
Formiminoglutamic aciduria is not contagious; you can’t catch it from someone else or pass it through everyday contact. In most cases, it’s a genetic condition caused by changes in a gene that helps the body break down the amino acid histidine.
The genetic transmission of Formiminoglutamic aciduria is autosomal recessive: when both parents carry one nonworking copy of the gene, each pregnancy has a 25% (1 in 4) chance of a child with the condition, a 50% chance the child will be a carrier, and a 25% chance of neither. Carriers usually have no symptoms and often don’t know they carry it. New mutations can happen, but most children with Formiminoglutamic aciduria are born to two carrier parents.
When to test your genes
Consider genetic testing if you or your child has unexplained developmental delay, anemia unresponsive to standard treatment, or lab signs of folate cycle problems, especially with a family history of similar issues. Testing is also reasonable before pregnancy or if consanguinity is present. Results can guide folinic acid therapy, monitoring, and family counseling.
Diagnosis
Formiminoglutamic aciduria is usually identified when a specific substance called FIGLU is found at high levels and then confirmed with targeted tests. The genetic diagnosis of Formiminoglutamic aciduria often combines lab measurements with DNA testing of the FTCD gene. Early and accurate diagnosis can help you plan ahead with confidence. For some families, the first clue appears on a newborn screen; for others, testing starts after concerns like anemia, slow growth, or developmental delays.
Your provider looks for patterns like developmental delays, feeding issues, growth concerns, or signs of anemia. A detailed family and health history can help identify inherited patterns.
A urine test measures FIGLU levels. Markedly elevated FIGLU supports Formiminoglutamic aciduria.
A blood test checks related amino acid patterns. Results can support but do not by themselves confirm the condition.
After a small histidine dose, urine is checked for a rise in FIGLU. A large increase suggests reduced FTCD enzyme activity. This test is less common when other methods are available.
Stages of Formiminoglutamic aciduria
Formiminoglutamic aciduria does not have defined progression stages. It’s mainly a lab finding that can have different causes, and many people have no symptoms, so it doesn’t follow a predictable pattern of getting worse over time. Different tests may be suggested to help confirm the cause, such as urine testing for FIGLU, blood tests for folate and vitamin B12, and sometimes genetic testing. Doctors usually monitor growth, development, and blood counts over time, since early symptoms of Formiminoglutamic aciduria can be subtle—or not present at all.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with formiminoglutamic aciduria, the outlook depends on the underlying cause. In many, the issue stems from low folate or vitamin B12, or from a medication effect, and correcting those can improve symptoms and lab findings within weeks to months. When the condition is due to a rare inherited enzyme change, outcomes vary—from mild learning challenges and speech delay to more noticeable developmental differences. Early care can make a real difference, especially when nutrition gaps are treated and developmental therapies start early.
Mortality is generally low when formiminoglutamic aciduria is recognized and treated, and most children and adults can expect a normal life span. Some may have periods where attention, growth, or energy dip during illnesses, while for others these concerns never become prominent. If early symptoms of formiminoglutamic aciduria include feeding difficulties or poor growth, nutrition support and vitamins often help stabilize things. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including diet quality and timely treatment of vitamin deficiencies.
When the condition links to a specific gene change, genetic testing can sometimes provide more insight into prognosis and help tailor follow-up. Ongoing follow-up with a metabolic or genetics clinic typically focuses on monitoring growth, development, blood counts, and vitamin status. With ongoing care, many people maintain good health, attend school or work, and take part in daily activities. Talk with your doctor about what your personal outlook might look like, including how often to recheck labs and whether family members should be screened.
Long-term effects
Formiminoglutamic aciduria usually has a favorable long‑term outlook, with many people staying healthy and reaching typical milestones. Long-term effects vary widely, and some people never develop noticeable health issues beyond a lab result. Others may see early-life anemia or mild developmental differences that tend to stabilize over time. Most reports suggest a normal life span and overall wellbeing.
Many have typical development, while some show mild delays in speech, language, or motor skills. These differences often become clearer in preschool or early school years. Some children later catch up or need limited educational support.
Thinking and learning skills range from average to mildly affected in formiminoglutamic aciduria. School challenges, when present, are usually modest and vary from child to child.
Some infants develop megaloblastic anemia, which can cause pallor and low energy. It often improves with time and may not recur later in childhood.
Many people with formiminoglutamic aciduria have no health problems and only show elevated FIGLU on lab testing. Over time, daily routines may look no different from peers.
How is it to live with Formiminoglutamic aciduria?
Living with formiminoglutamic aciduria often means monitoring energy, growth, and learning closely, because some people have no symptoms while others face developmental delays, feeding challenges, or anemia tied to problems processing folate and histidine. Daily life can involve regular checkups, targeted nutrition or folinic acid therapy as advised by a specialist, and support services at school to help with speech, motor skills, or attention. Families and caregivers may feel the weight of appointments and uncertainty, but many find a steady rhythm with a coordinated care team, clear action plans for illness or stress, and connections to rare disease communities that offer practical tips and reassurance.
Treatment and drugs
Formiminoglutamic aciduria is treated by addressing folate metabolism and any related nutritional gaps. Doctors often start folinic acid (leucovorin), a form of folate that can bypass the metabolic block, which may help lower excess FIGLU and support growth and development. A high-protein diet is usually not needed long term, but some clinicians suggest moderating very high histidine intake and ensuring balanced nutrition with adequate vitamins, including B12, based on blood tests. Supportive care can make a real difference in how you feel day to day, so hearing, vision, learning, and motor skills are checked regularly, with therapies added if needed. Keep track of how you feel, and share this with your care team so they can adjust dosing and follow-up over time.
Non-drug treatment
Care for formiminoglutamic aciduria centers on everyday nutrition, growth, and development, tailored to each child over time. Non-drug treatments often lay the foundation for steady progress and can complement any medical care your team suggests. Plans are usually led by a metabolic clinic and a registered dietitian, with regular check-ins to track learning, movement, and key lab results. Families also benefit from clear education and simple steps to handle common illnesses at home.
Work with a dietitian to aim for balanced protein without very high-protein fads or histidine-containing supplements. Emphasize varied, folate-rich foods like leafy greens, beans, and fortified grains.
Regular visits help track height, weight, and energy levels over time. Doctors may check blood counts and liver enzymes to spot problems early.
Early symptoms of formiminoglutamic aciduria can be subtle, so scheduled checks of speech, motor skills, and learning are helpful. Screening guides whether added supports are needed.
Speech, occupational, and physical therapy can build communication, coordination, and daily living skills. Therapy plans adjust as needs change at home and school.
Your genes may have an impact on how drugs work for you
Some medicines for formiminoglutamic aciduria can work differently depending on variants in genes that process folate and histidine. Genetic testing helps clinicians choose doses or alternatives that fit your biology, aiming for better effect with fewer side effects.
Pharmacological treatments
Treatment for day-to-day life often focuses on supporting the body’s folate pathway so energy, growth, and learning can stay on track. Because early symptoms of Formiminoglutamic aciduria can be mild or absent, doctors may suggest simple vitamin-based treatments and check lab markers over time. Not everyone responds to the same medication in the same way. If one approach doesn’t help, another form of folate may be tried and doses adjusted based on response.
This common, low-cost vitamin is often tried first to support folate pathways and may lower FIGLU levels. First-line medications are those doctors usually try first, based on safety, evidence, and how well they’re tolerated.
This active form of folate can bypass some metabolic steps and may help if folic acid isn’t enough. In Formiminoglutamic aciduria, it’s considered when symptoms persist or urine FIGLU stays high despite folic acid. If one option isn’t effective, second-line or alternative drugs may be offered.
Genetic influences
In most cases, formiminoglutamic aciduria stems from changes in a gene called FTCD, which makes an enzyme that helps the body break down the amino acid histidine and use folate. When this enzyme is working like a dimmer switch turned down too low, a substance called formiminoglutamate (often shortened to FIGLU) can build up, which is how the condition gets its name. The condition follows an autosomal recessive pattern: if both parents carry one FTCD change, each child has a 25% (1 in 4) chance to be affected, a 50% (1 in 2) chance to be a carrier, and a 25% chance to inherit neither change. A “carrier” means you hold the gene change but may not show symptoms. Even among people with the same FTCD change, the features can range from no symptoms to mild issues, and early symptoms of formiminoglutamic aciduria can differ from one child to another. Genetic testing of the FTCD gene can confirm the cause and help families understand whether formiminoglutamic aciduria is inherited in their family.
Is Formiminoglutamic aciduria genetic?
Genetics is central in formiminoglutamic aciduria, usually caused by inherited changes in the FTCD gene. These variants disrupt folate‑related processing of the amino acid histidine, leading to excessive formiminoglutamate. Most cases are autosomal recessive; carrier testing and family counseling can help.
Pharmacogenetics—how genetics influence drug effects
Because formiminoglutamic aciduria stems from changes in a gene (FTCD) that helps the body use folate, treatment choices are shaped by that biology. Alongside your medical history and lab results, genetic testing can confirm the diagnosis and help guide which folate-based therapy may help. Many doctors favor folinic acid (leucovorin), an active form of folate, because it can support the slowed pathway; the dose is tailored over time using growth, blood counts, and routine monitoring.
Medicines that lower folate activity—such as methotrexate, trimethoprim, or some seizure medicines—may call for extra caution, closer monitoring, or dose changes in people with formiminoglutamic aciduria. Genetics doesn’t decide every detail of response, but it does help doctors tailor drug treatment for formiminoglutamic aciduria to reduce side effects and avoid trial and error where possible.
Interactions with other conditions
Formiminoglutamic aciduria often intersects with conditions that affect vitamin absorption and use, especially low folate (vitamin B9) or low vitamin B12. Doctors call it a “comorbidity” when two conditions occur together. When folate or B12 is also low—sometimes due to celiac disease, inflammatory bowel disease, or after stomach or bowel surgery—FIGLU levels can rise and anemia or fatigue can be more noticeable; for some, early symptoms of Formiminoglutamic aciduria may show up during these times. Certain medications that reduce folate activity, such as some chemotherapy or anti-seizure drugs, can also increase FIGLU and may worsen tiredness or mouth sores linked with folate deficiency. Periods of illness, rapid growth, or pregnancy increase the body’s need for folate, which can unmask or intensify features of the condition. Let your care team know about all diagnoses and medicines so they can plan monitoring and vitamin support that fits your overall health.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described children who struggled to grow, tired easily, and had learning challenges without a clear cause. Families sometimes remembered a relative who seemed well in early childhood but later developed anemia, mouth sores, or behavior changes that puzzled doctors. These day-to-day details eventually pointed to a metabolic issue—one that affects how the body handles folate and certain building blocks of protein.
First described in the medical literature as a buildup of a compound called formiminoglutamic acid in the urine, Formiminoglutamic aciduria came to light in the mid-20th century when urine screening for unusual chemicals became possible. Initially understood only through symptoms, later lab methods could directly measure this substance and link it to a block in a vitamin-dependent step of metabolism. As reports accumulated, clinicians noticed that some people with Formiminoglutamic aciduria also had megaloblastic anemia, a type of anemia often tied to folate or vitamin B12 problems, suggesting a connection between the condition and folate processing in the body.
Over time, descriptions became more precise. Researchers narrowed the problem to an enzyme step that transfers a small chemical group during the breakdown of histidine, an amino acid. This step needs a form of folate to work properly. When it stalls, formiminoglutamic acid builds up and spills into urine—a clue that helped doctors recognize Formiminoglutamic aciduria even when outward signs were subtle. Not everyone had the same course: some children showed developmental and learning differences early on, while others came to attention because of anemia or because a family member was screened.
Advances in genetics confirmed what careful observation had suggested. Changes in a gene that guides this folate-dependent enzyme explained why the pathway was blocked in some families. In recent decades, knowledge has built on a long tradition of observation. Newborn and metabolic screening programs in some regions identified additional cases, revealing that Formiminoglutamic aciduria ranges from mild to more noticeable forms. This explained why early reports made it seem very rare: people with milder versions were simply missed.
Current studies build on a long tradition of observation to clarify which features are due to the enzyme block itself and which come from low folate availability in tissues. That distinction matters because some individuals improve with targeted vitamin support, while others need broader care for learning and behavioral needs. Today, the history of Formiminoglutamic aciduria shows how careful symptom tracking, simple urine tests, and later genetic tools together turned scattered stories into a clear condition—one that clinicians can recognize earlier and manage more confidently.